Ecabet

Gastric mucosal injury is the core pathological basis of diseases such as peptic ulcer and chronic gastritis. Traditional mucosal protective agents mostly rely on a single barrier effect or acid suppression assistance, and there are still clinical pain points of slow repair speed and high recurrence rate. Ecabet is a terpene class gastric mucosal protective agent, whose mechanism of action breaks through the traditional protection logic. It can not only form a physical barrier by binding to albumin at the gastric mucosal injury site to isolate the erosion of gastric acid and pepsin, but also directly promote the synthesis of endogenous prostaglandins, increase mucus secretion, and inhibit the activity of Helicobacter pylori urease to exert a bacteriostatic effect. It is mainly used clinically to improve gastric mucosal lesions in gastric ulcer, acute gastritis and acute exacerbation of chronic gastritis, and the applicable population covers adult patients with chronic gastritis, people with Helicobacter pylori infection combined with mucosal injury, and high-risk groups of gastric mucosal injury caused by the use of non-steroidal anti-inflammatory drugs.

The global market size of ecabet is approximately USD 320 million, of which the Asia-Pacific region accounts for more than 75%. The core driving factor is that the prevalence of chronic gastritis and gastric ulcer in East Asia has long remained at a relatively high level of 15%-23%, and the clinical use proportion of mucosal protective drugs has increased year by year. The compound annual growth rate of the Chinese market in the past three years has reached 8.7%. The current competitive landscape is dominated by generic preparations, with the original research product accounting for about 22% of the market. 10 domestic enterprises have obtained preparation approvals, the localization rate of API has exceeded 90%, and it has not been included in the national centralized volume-based procurement scope.

The original research enterprise of ecabet is Japan's Tanabe Mitsubishi Pharmaceutical Co., Ltd., and the original trade name is "Gaslon N". Its core compound patent expired globally in 2009, and the compound patent in China also expired in 2009. The main dosage form approved for the original research is granules, with a specification of 1.5g per bag (containing 1.0g of ecabet). This product has been included in the Chinese Listed Drug Catalogue as a reference preparation, and is also included in the FDA Reference Preparation Catalogue. As of now, the Center for Drug Evaluation of the National Medical Products Administration of China has publicly announced 12 ecabet API registration information, of which 8 are in status A and can be legally associated with preparation declarations. 11 ecabet granule preparation varieties have been approved for marketing in China. (Data as of June 2025, please refer to the official CDE website for the latest information)

In response to the R&D and quality control needs of ecabet, CATO provides a full set of impurity reference standards for this API. Most of the products are in stock, and in-stock products ordered before 16:00 will be shipped on the same day. They fully comply with the compliance requirements of multiple regulations such as the Chinese Pharmacopoeia and FDA, and can be directly used for API related substance testing, stability research and submission of declaration materials, helping enterprises efficiently complete R&D and quality compliance work.